Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$728.00K$728.00Kderived−50.8% vs Q4 2018 Net Income-$29.36M-$29.36MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$30,355,000N/M Operating Cash Flowderived-$12,528,000N/M Free Cash Flowderived-$12,695,000N/M Margins · derivedOperating margin-4169.6%−2021.8 pt vs Q4 2018
Net margin-4033.5%−1587.7 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 27, 2020 · 58 d after period end